Knights of Columbus Asset Advisors LLC Has $4.41 Million Position in AtriCure, Inc. (NASDAQ:ATRC)

Knights of Columbus Asset Advisors LLC raised its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 165.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 123,540 shares of the medical device company's stock after purchasing an additional 77,055 shares during the period. Knights of Columbus Asset Advisors LLC owned 0.26% of AtriCure worth $4,409,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Snowden Capital Advisors LLC raised its position in shares of AtriCure by 3.5% in the first quarter. Snowden Capital Advisors LLC now owns 7,400 shares of the medical device company's stock valued at $307,000 after buying an additional 250 shares during the last quarter. State of Wyoming raised its position in shares of AtriCure by 34.6% in the second quarter. State of Wyoming now owns 1,030 shares of the medical device company's stock valued at $51,000 after buying an additional 265 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of AtriCure by 4.4% in the second quarter. PNC Financial Services Group Inc. now owns 6,791 shares of the medical device company's stock valued at $335,000 after buying an additional 286 shares during the last quarter. Rockefeller Capital Management L.P. raised its position in shares of AtriCure by 15.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 2,444 shares of the medical device company's stock valued at $108,000 after buying an additional 319 shares during the last quarter. Finally, Mariner LLC raised its position in shares of AtriCure by 6.3% in the fourth quarter. Mariner LLC now owns 5,715 shares of the medical device company's stock valued at $254,000 after buying an additional 337 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Insider Buying and Selling at AtriCure

In other AtriCure news, insider Karl S. Dahlquist sold 8,231 shares of the firm's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $37.36, for a total transaction of $307,510.16. Following the transaction, the insider now owns 52,839 shares of the company's stock, valued at approximately $1,974,065.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other AtriCure news, insider Justin J. Noznesky sold 1,500 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $30.39, for a total transaction of $45,585.00. Following the transaction, the insider now owns 72,784 shares of the company's stock, valued at approximately $2,211,905.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Karl S. Dahlquist sold 8,231 shares of the firm's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $37.36, for a total transaction of $307,510.16. Following the transaction, the insider now owns 52,839 shares of the company's stock, valued at approximately $1,974,065.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,116 shares of company stock valued at $468,797. Company insiders own 3.20% of the company's stock.

AtriCure Stock Performance

Shares of ATRC stock traded down $0.19 during trading hours on Friday, reaching $23.20. The stock had a trading volume of 470,018 shares, compared to its average volume of 760,414. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.57 and a quick ratio of 2.66. AtriCure, Inc. has a twelve month low of $22.42 and a twelve month high of $59.61. The firm has a 50-day simple moving average of $30.83 and a 200-day simple moving average of $34.23. The firm has a market capitalization of $1.12 billion, a PE ratio of -35.15 and a beta of 1.38.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Thursday, February 15th. The medical device company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. AtriCure had a negative net margin of 7.62% and a negative return on equity of 7.55%. The business had revenue of $106.50 million for the quarter, compared to analysts' expectations of $103.68 million. During the same quarter last year, the company earned ($0.09) EPS. The company's revenue for the quarter was up 21.0% compared to the same quarter last year. As a group, equities analysts forecast that AtriCure, Inc. will post -0.71 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ATRC shares. StockNews.com lowered shares of AtriCure from a "hold" rating to a "sell" rating in a research report on Wednesday, March 27th. UBS Group upped their price target on shares of AtriCure from $57.00 to $58.00 and gave the stock a "buy" rating in a research report on Friday, February 16th. Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 price target on shares of AtriCure in a research report on Wednesday, April 10th. Finally, Stifel Nicolaus dropped their price target on shares of AtriCure from $50.00 to $42.00 and set a "buy" rating for the company in a research report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to MarketBeat, AtriCure currently has an average rating of "Moderate Buy" and an average target price of $55.57.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.